Heron Therapeuti (HRTX) - Total Liabilities
Based on the latest financial reports, Heron Therapeuti (HRTX) has total liabilities worth $237.08 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore HRTX shareholders equity momentum to track the company's year-over-year net asset growth rate.
Heron Therapeuti - Total Liabilities Trend (1987–2025)
This chart illustrates how Heron Therapeuti's total liabilities have evolved over time, based on quarterly financial data. See how much free cash does Heron Therapeuti generate to measure how efficiently the company converts operating cash flow to free cash.
Heron Therapeuti Competitors by Total Liabilities
The table below lists competitors of Heron Therapeuti ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Matrimony.Com Limited
NSE:MATRIMONY
|
India | Rs2.20 Billion |
|
Tunas Alfin Tbk
JK:TALF
|
Indonesia | Rp583.40 Billion |
|
Pelican Acquisition Corporation Ordinary Shares
NASDAQ:PELI
|
USA | $583.17K |
|
Data Communications Management Ltd
TO:DCM
|
Canada | CA$321.00 Million |
|
Immunoprecise Antibodies Ltd
NASDAQ:IPA
|
USA | $20.82 Million |
|
TMT Steel Public Company Limited
BK:TMT
|
Thailand | ฿5.04 Billion |
|
Caturkarda Depo Bangunan PT Tbk
JK:DEPO
|
Indonesia | Rp990.41 Billion |
|
TMT Investments PLC
LSE:TMT
|
UK | $661.36K |
Liability Composition Analysis (1987–2025)
This chart breaks down Heron Therapeuti's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Heron Therapeuti.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 25.95 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.96 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Heron Therapeuti's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Heron Therapeuti (1987–2025)
The table below shows the annual total liabilities of Heron Therapeuti from 1987 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $241.54 Million | -9.47% |
| 2024-12-31 | $266.80 Million | +4.02% |
| 2023-12-31 | $256.48 Million | +8.05% |
| 2022-12-31 | $237.38 Million | +4.05% |
| 2021-12-31 | $228.14 Million | +94.88% |
| 2020-12-31 | $117.06 Million | +7.45% |
| 2019-12-31 | $108.95 Million | +18.40% |
| 2018-12-31 | $92.02 Million | -10.81% |
| 2017-12-31 | $103.17 Million | +16.27% |
| 2016-12-31 | $88.73 Million | +349.62% |
| 2015-12-31 | $19.73 Million | +44.90% |
| 2014-12-31 | $13.62 Million | +94.79% |
| 2013-12-31 | $6.99 Million | +68.32% |
| 2012-12-31 | $4.15 Million | +12.48% |
| 2011-12-31 | $3.69 Million | +131.54% |
| 2010-12-31 | $1.59 Million | -25.99% |
| 2009-12-31 | $2.15 Million | -48.71% |
| 2008-12-31 | $4.20 Million | -43.79% |
| 2007-12-31 | $7.48 Million | +43.99% |
| 2006-12-31 | $5.19 Million | +87.71% |
| 2005-12-31 | $2.77 Million | -3.29% |
| 2004-12-31 | $2.86 Million | +51.16% |
| 2003-12-31 | $1.89 Million | -19.15% |
| 2002-12-31 | $2.34 Million | -46.02% |
| 2001-12-31 | $4.33 Million | -25.74% |
| 2000-12-31 | $5.84 Million | -49.24% |
| 1999-12-31 | $11.50 Million | +33.72% |
| 1998-12-31 | $8.60 Million | -38.57% |
| 1997-12-31 | $14.00 Million | +4.48% |
| 1996-12-31 | $13.40 Million | -25.14% |
| 1995-12-31 | $17.90 Million | +52.99% |
| 1994-12-31 | $11.70 Million | -15.83% |
| 1993-12-31 | $13.90 Million | +71.60% |
| 1992-12-31 | $8.10 Million | +26.56% |
| 1991-12-31 | $6.40 Million | +20.75% |
| 1990-12-31 | $5.30 Million | +43.24% |
| 1989-12-31 | $3.70 Million | +5.71% |
| 1988-12-31 | $3.50 Million | -7.89% |
| 1987-12-31 | $3.80 Million | -- |
About Heron Therapeuti
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It … Read more